<DOC>
	<DOC>NCT02486302</DOC>
	<brief_summary>The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, or plaque psoriasis. In so doing, particular attention will be paid to the proportion of those patients who only attain the desired treatment goal after 12 weeks of treatment. The primary efficacy end point for the study is the proportion of patients who attain the desired treatment goal after 12 and 24 weeks,</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Confirmed diagnosis of RA, axSpA, PsA or PsO No prior treatment with etanercept and eligibility for treatment with etanercept according to the summary of product characteristics. The contraindications, special warnings, and precautions according to the summary of product characteristics for etanercept shall apply. The additional documentation of the patient in another postmarketing study with etanercept is not permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>